

1. Record Nr.	UNINA9910779511503321
Titolo	Infliximab [[electronic resource]] : pharmacology, uses and limitations // Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors
Pubbl/distr/stampa	New York, : Nova Science Publishers, c2012
ISBN	1-61942-345-6
Descrizione fisica	1 online resource (204 p.)
Collana	Immunology and immune system disorders
Altri autori (Persone)	Fajardo GaitanMontserrat Medrano AcevedoAntonio D
Disciplina	615.7/94
Soggetti	Anti-inflammatory agents Infliximab - Therapeutic use Infliximab
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Infliximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections"" ""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohna€s Disease ""; ""Fistulizing Crohna€s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing "" ""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations

""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References "";
""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract "";
""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and
Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution "";
""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration "";
""2.6. Pharmacogenomics""
""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other
Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c)
Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation
Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g)
Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1.
Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus
Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure
""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
""4.8. Neurological Events ""
